Gonadotropin and steroid receptors as prognostic factors in advanced ovarian cancer: a retrospective study

  • Lorenzo Alonso
  • Elena Gallego
  • Francisco Jesús González
  • Alfonso Sánchez-Muñoz
  • Esperanza Torres
  • Bella Isabel Pajares
  • Stephanie Leeflang
  • Camelia Baha
Research Articles



Ovarian cancer is a chemosensitive tumour, but two thirds of women have a recurrence during the follow-up, even after an optimal surgical debulking followed by chemotherapy with a platinum and a taxane compound. Cytotoxic drugs are used in a second- or third-line setting but tumour progression is the rule. Also patients with the same histology achieve different outcomes in terms of survival. We decided to study gonadotropin and steroid receptors and to consider if these histological markers could select patients with different prognosis.

Materials and methods

In our study we have measured by immunohistochemistry oestrogen, progestin and gonadotropin-releasing hormone receptors (Gn-RHRs) in paraffin-embedded ovarian cancer tissue in a sample of 62 consecutive patients with advanced ovarian cancer treated with surgery and adjuvant chemotherapy. Descriptive methods, a survival analysis (Kaplan-Meier) and a Cox regression analysis were done.


Oestrogen receptors (ERs) were positive in 65% of patients and the same positivity was obtained for progestin receptors (PRs), with 74% showing some positivity for Gn-RHR receptors. Maximal cytoreduction and ERs, but not gonadotropin receptors, were independently associated with overall survival, with better survival for oestrogennegative tumours. No association was established for progression-free survival.


We can conclude that ER status in our series is an independent prognostic factor for ovarian cancer with better survival for oestrogen-negative receptor tumours. PRs could also have a prognostic role in association with ERs.


Ovarian cancer Prognostic factor Oestrogen receptor Gonadotropin-releasing hormone receptor 


  1. 1.
    Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92:699–708CrossRefPubMedGoogle Scholar
  2. 2.
    McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6CrossRefPubMedGoogle Scholar
  3. 3.
    Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194–3200CrossRefPubMedGoogle Scholar
  4. 4.
    Bristow RE, Tomacruz RS, Armstrong DK et al (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Clin Oncol 20:1248–1259CrossRefGoogle Scholar
  5. 5.
    Hoskins WJ, Bundy BN, Thigpen JT et al (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166CrossRefPubMedGoogle Scholar
  6. 6.
    Hoskins WJ, McGuire WP, Brady MF et al (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170:974–980PubMedGoogle Scholar
  7. 7.
    Riman T, Dickman PW, Nilsson S et al (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94:497–504PubMedGoogle Scholar
  8. 8.
    Folsom AR, Anderson JP, Ross JA (2004) Estrogen replacement therapy and ovarian cancer. Epidemiology 15:100–104CrossRefPubMedGoogle Scholar
  9. 9.
    Riman T, Dickman PW, Nilsson S et al (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156:363–373CrossRefPubMedGoogle Scholar
  10. 10.
    Sit AS, Modugno F, Weissfeld JL et al (2002) Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol Oncol 86:118–123CrossRefPubMedGoogle Scholar
  11. 11.
    Leung PC, Cheng CK, Zhu XM (2003) Multi-factorial role of GnRH-I and GnRH-II in the human ovaries. Mol Cell Endocrinol 202:145–153PubMedGoogle Scholar
  12. 12.
    Minegishi T, Kameda T, Hirakawa T et al (2000) Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin Cancer Res 6:2764–2770PubMedGoogle Scholar
  13. 13.
    Furui T, Imai A, Tamaya T (2002) Intratumoral level of gonadotropin-releasing hormone in ovarian and endometrial cancers. Oncol Rep 9:349–352PubMedGoogle Scholar
  14. 14.
    Konishi I, Kuroda H, Mandai M (1999) Review: gonadotropin and development of ovarian cancer. Oncology 57[Suppl 2]:45–48CrossRefPubMedGoogle Scholar
  15. 15.
    Du BA, Meier W, Luck HJ et al (2002) Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13:251–257CrossRefPubMedGoogle Scholar
  16. 16.
    Paskeviciute L, Roed H, Engelholm A (2002) No rules without exception: a long-term complete remission observed in a study using a LH-RH agonist in platinum-refractory ovarian cancer. Eur J Cancer 138[Suppl 6]:S73CrossRefGoogle Scholar
  17. 17.
    Balbi G, Piano LD, Cardone A et al (2004) Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 14:799–803CrossRefPubMedGoogle Scholar
  18. 18.
    Perez-Gracia JL, Carrasco EM (2002) Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research. Gynecol Oncol 84:201–209CrossRefPubMedGoogle Scholar
  19. 19.
    Bowman A, Gabra H, Langdon SP et al (2002) CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 8:2233–2239PubMedGoogle Scholar
  20. 20.
    Papadimitriou CA, Markaki S, Siapkaras J et al (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66:112–117CrossRefPubMedGoogle Scholar
  21. 21.
    Walker G, MacLeod K, Williams ARW et al (2007) Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer. Clin Cancer Res 13:1438–1444CrossRefPubMedGoogle Scholar
  22. 22.
    Lindgren P, Bäckström T, Mählck CG et al (2001) Steroid receptors and hormones in relation to cell proliferation and apoptosis in poorly differentiated epithelial ovarian tumors. Int J Oncol 19:31–38PubMedGoogle Scholar
  23. 23.
    Lee P, Rosen DG, Zhu C et al (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96:671–677CrossRefPubMedGoogle Scholar
  24. 24.
    Völker P, Gründker C, Schmidt O (2002) Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 186:171–179CrossRefPubMedGoogle Scholar
  25. 25.
    Imai A, Ohno T, Lida K et al (1994) Gonadotropin-releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 74:2555–2561CrossRefPubMedGoogle Scholar
  26. 26.
    Hoskins WJ, Bundy B, Thigpen JT et al (1992) The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47:159–166CrossRefPubMedGoogle Scholar
  27. 27.
    Fujimoto J, Alam SM, Jahan I et al (2007) Clinical implication of estrogen-related receptor (ERR) expression in ovarian cancers. J Steroid Biochem Mol Biol 104:301–304CrossRefPubMedGoogle Scholar
  28. 28.
    Münstedt K, Steen J, Knauf AG et al (2000) Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89:1783–1791CrossRefPubMedGoogle Scholar
  29. 29.
    Hogdall EV, Christensen L, Hogdall CK et al (2007) Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the ‘MALOVA’ ovarian cancer study. Oncol Rep 18:1051–1059PubMedGoogle Scholar
  30. 30.
    Arias-Pulido H, Smith HO, Joste NE et al (2009) Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol 114:480–485CrossRefPubMedGoogle Scholar
  31. 31.
    Bookman MA (2005) Is there still a role for hormonal therapy? Int J Gynecol Cancer 15[Suppl 3]:291–297CrossRefPubMedGoogle Scholar
  32. 32.
    Li YF, Hu W, Fu SQ et al (2008) Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer 18:600–614CrossRefPubMedGoogle Scholar
  33. 33.
    Brekelmans CT, Seynaeve C, Menke-Pluymers M et al (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17:391–400CrossRefPubMedGoogle Scholar
  34. 34.
    Chetrit A, Hirsh-Yechezkel G, Ben-David Y et al (2008) Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol 26:20–25CrossRefPubMedGoogle Scholar

Copyright information

© Feseo 2009

Authors and Affiliations

  • Lorenzo Alonso
    • 1
  • Elena Gallego
    • 2
  • Francisco Jesús González
    • 3
  • Alfonso Sánchez-Muñoz
    • 1
  • Esperanza Torres
    • 1
  • Bella Isabel Pajares
    • 1
  • Stephanie Leeflang
    • 1
  • Camelia Baha
    • 1
  1. 1.Medical Oncology ServiceHospital Universitario Virgen de la VictoriaMálagaSpain
  2. 2.Pathology DepartmentHospital Universitario Virgen de la VictoriaMálagaSpain
  3. 3.Fundación IMABISMálagaSpain

Personalised recommendations